Synbio International has launched its Healing Force™ nutraceutical product line, starting with Anxiety Relief, under exclusive U.S. and Canadian licensing. The company is also advancing clinical trials for its AI-powered NIMS™ facial-analysis platform aimed at non-invasive mental health screening for conditions like depression and PTSD. Synbio is pursuing funding strategies to avoid shareholder dilution while targeting significant market demand for objective mental health tools. Upcoming milestones include completing the commercial launch, starting an Australian feasibility study, and expanding clinical validation in the U.S.
Synbio International's healthcare growth strategy is highlighted here alongside Pluang's health sector market data. For readers following health stocks, here is Pluang's market snapshot as of Oct 01, 2026 19:31 WIB: out of 100 priced US health-sector stocks, 60 rose and 33 fell today. Notable movers include Alcon AG (ALC) at USD 63.88 with a 1-day change of -1.34% and 100% buy order activity, Smith & Nephew plc (SNN) at USD 26.60 with a -1.34% change, and Abeona Therapeutics Inc (ABEO) at USD 5.18 with a -1.33% change.
An analyst at Truist Financial raised Wells Fargo's price target to $95, suggesting a 20.74% upside from its current price. This optimism is driven by expected strong third-quarter earnings of $1.85 per share and $22.34 billion in revenue, surpassing...
Oklo is developing advanced fast-fission reactors to power future data centers and industrial hubs, aiming to lead in carbon-free energy. Piper Sandler reaffirmed an "Overweight" rating on the stock, reflecting confidence in Oklo's growth prospects. ...
Nike is set to release its quarterly earnings on October 1, 2026, with analysts forecasting an EPS of $0.44 and revenue of $11.32 billion, both down from last year. The company's stock has fallen 80% this year, hitting 13-year lows, reflecting a chal...
Lamb Weston is set to report Q3 earnings with analysts forecasting an EPS of $0.59, down from $0.74 last year, and revenue around $1.65 billion, nearly flat compared to the prior year. The company’s "Focus to Win" strategy has generated over $100 mil...
Synopsys, Inc. is rated Strong Buy with a $771 price target due to its integration of agentic AI into its electronic design automation (EDA) platform and a strong outlook for growth in EDA and intellectual property (IP). The company’s Factory 2 model...
